Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 26, Number 10—October 2020

Research

Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013–2017

Reiko Shimbashi, Motoi SuzukiComments to Author , Bin Chang, Hiroshi Watanabe, Yoshinari Tanabe, Koji Kuronuma, Kengo Oshima, Takaya Maruyama, Hiroaki Takeda, Kei Kasahara, Jiro Fujita, Junichiro Nishi, Tetsuya Kubota, Keiko Tanaka-Taya, Tamano Matsui, Tomimasa Sunagawa, Kazunori Oishi, and Adult IPD Study Group
Author affiliations: National Institute of Infectious Diseases, Tokyo, Japan (R. Shimbashi, M. Suzuki, B. Chang, K. Tanaka-Taya, T. Matsui, T. Sunagawa, K. Oishi); Tohoku University Graduate School of Medicine, Miyagi, Japan (R. Shimbashi, M. Suzuki, K. Oshima); Kurume University School of Medicine, Fukuoka, Japan (H. Watanabe); Niigata Prefectural Shibata Hospital, Niigata, Japan (Y. Tanabe); Sapporo Medical University School of Medicine, Hokkaido, Japan (K. Kuronuma); National Hospital Organization Mie National Hospital, Mie, Japan (T. Maruyama); Yamagata Saisei Hospital, Yamagata, Japan (H. Takeda); Nara Medical University, Nara, Japan (K. Kasahara); Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan (J. Fujita); Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan (J. Nishi); Kochi Medical School, Kochi University, Kochi, Japan (T. Kubota); Toyama Institute of Health, Toyama, Japan (K. Oishi)

Main Article

Figure

Percentage of vaccine-covered serotypes among pneumococcal isolates from 1,108 invasive pneumococcal disease patients >20 years of age, stratified by year and age group, Japan, 2013–2017. NVT, non–vaccine type; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.

Figure. Percentage of vaccine-covered serotypes among pneumococcal isolates from 1,108 invasive pneumococcal disease patients >20 years of age, stratified by year and age group, Japan, 2013–2017. NVT, non–vaccine type; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.

Main Article

Page created: August 05, 2020
Page updated: September 17, 2020
Page reviewed: September 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external